Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma

Published 2021 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
Authors
Keywords
-
Journal
JAMA Network Open
Volume 4, Issue 1, Pages e2033761
Publisher
American Medical Association (AMA)
Online
2021-01-20
DOI
10.1001/jamanetworkopen.2020.33761

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.